Short-term Efficacy and Safety of a Latanoprost/Carteolol Fixed Combination Switched From Concomitant Therapy to in Patients With Primary Open-angle Glaucoma or Ocular Hypertension.
Inoue Kenji, Shiokawa Minako, Iwasa Mayumi, Ishida Kyoko, Tomita Goji
AI Summary
Switching glaucoma patients from separate latanoprost and carteolol drops to a fixed-combination maintained IOP control, improved ocular surface health, and enhanced patient preference, offering a simpler, well-tolerated treatment option.
Abstract
Purpose
We prospectively investigated the efficacy and safety of switching from concomitant latanoprost and carteolol hydrochloride (CH) to a latanoprost/carteolol fixed combination (LCFC) in patients with primary open-angle glaucoma or ocular hypertension.
Patients and methods: A total of 43 patients (43 eyes) who were using latanoprost (once daily in the evening) and CH (once daily in the morning) concomitantly were switched to LCFC (once daily in the morning) with no washout interval. The primary efficacy endpoint was change in intraocular pressure (IOP) between baseline (before switching) and 1 and 3 months after switching. Systemic blood pressure and pulse rate, corneal epithelial defects, and tear film break-up time (TBUT) were also compared before and 1 and 3 months after switching. A questionnaire was administered 1 month after switching to investigate ocular comfort and treatment preferences. Adverse reactions and dropouts were recorded.
Results
There was no significant difference in IOP after switching to LCFC (15.0±2.6, 15.1±2.4, and 15.0±2.4 mm Hg at baseline and at 1 and 3 months, respectively). There was a significant decrease in corneal epithelial defects and significant increase in TBUT, without significant changes in systemic blood pressure or pulse rate. Three patients (7.3%) preferred concomitant latanoprost and CH; 33 (80.5%) preferred the LCFC. One patient each (9.3%) discontinued treatment because of foreign body sensation, blepharitis, increased IOP, or loss to follow-up.
Conclusions
Switching from concomitant latanoprost and CH to LCFC led to similar IOP control with good safety and patient acceptance, at least in the short term.
MeSH Terms
Shields Classification
Key Concepts5
Switching from concomitant latanoprost and carteolol hydrochloride (CH) to a latanoprost/carteolol fixed combination (LCFC) resulted in no significant difference in intraocular pressure (IOP) at baseline (15.0 ± 2.6 mmHg) and at 1 (15.1 ± 2.4 mmHg) and 3 months (15.0 ± 2.4 mmHg) after switching.
Switching from concomitant latanoprost and carteolol hydrochloride (CH) to a latanoprost/carteolol fixed combination (LCFC) led to a significant decrease in corneal epithelial defects and a significant increase in tear film break-up time (TBUT) in patients with primary open-angle glaucoma or ocular hypertension.
Switching from concomitant latanoprost and carteolol hydrochloride (CH) to a latanoprost/carteolol fixed combination (LCFC) did not result in significant changes in systemic blood pressure or pulse rate in patients with primary open-angle glaucoma or ocular hypertension.
After switching from concomitant latanoprost and carteolol hydrochloride (CH) to a latanoprost/carteolol fixed combination (LCFC), 33 out of 41 patients (80.5%) preferred the LCFC, while 3 patients (7.3%) preferred concomitant latanoprost and CH.
Discontinuation of treatment after switching to latanoprost/carteolol fixed combination (LCFC) occurred in 4 patients (9.3%) due to foreign body sensation, blepharitis, increased IOP, or loss to follow-up, with one patient for each reason.
Related Articles5
How latanoprost changed glaucoma management.
ReviewOcular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride.
Clinical TrialSpanish multicenter tafluprost tolerability study.
Observational StudyEffects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface -- a multicentre randomized single-masked study.
Randomized Controlled TrialA phase III study comparing preservative-free latanoprost eye drop emulsion with preserved latanoprost in open-angle glaucoma or ocular hypertension.
Randomized Controlled TrialIs this article assigned to the wrong chapter(s)? Let us know.